In our dynamic world, a better syndromic Point-of-Care testing is key to improve linkage to care. It enables swift diagnosis, timely treatment, and enhanced patient outcomes. Syndromic screening is a vital tool in controlling infectious diseases, reducing spread, and preventing outbreaks. However, it is often limited to lab settings and rarely available at the Point-of-Care.
Beyond patient convenience, it optimizes resource use, ensuring healthcare remains accessible and fair to all. MagIA diagnostics, driven by these ideals, is pioneering an innovative on-the-spot system, the MforScreen. It is fusing an easy-to-use cartridge approach with an easy-to-deploy analyzer, all dedicated to raising the bar at the point-of need.
Key advantages
Innovative rapid and portable panel testing
Simple
Portable
Multiplexed
Fast
Generic
Flexible
Our solutions
Active ingredient analysis
MagIA analyzer
Easy to deploy: Our key for a flexible and simple solution
Our MforScreen analyzer presents many benefits:
– Portability: A system weight below 3 kg. Get it done wherever needed
– Autonomy: 2 removable batteries for up to 8 hours off the grid
– Modularity: Analyze either 1 or 2 cartridges in parallel
– Objectivity: unambiguous and qualitative results
MforScreen can be upgraded using the following accessories:
– Mini-printer: for patient results printing
– Hand-held scanner: for patient identification
MagIA kit
Easy to use: From a single drop of blood
Each MagIA test is composed of a cartridge, a lancet, a pipette and a ready to use MagIA diluent dropper bottle.
How does it work?
1. Collect 50 µl capillary blood using lancet and pipette
2. Dilute blood in the dropper bottle
3. Fill the cartridge
4. Insert the cartridge in MagIA analyzer
5. Get results in 12 minutes
MagIA IBC
Syndromic screening of HIV, Hepatitis B & C
As per the World Health Organization (WHO), approximately 400 million individuals worldwide are currently infected with HIV and Viral Hepatitis. Each year, there are 4.5 million new infections and 1.8 million fatalities attributed to these diseases. HIV and Viral Hepatitis are pressing global health concerns.
In Europe, there are over 80 million people at risk to be infected. HIV is regularly tested on the spot, whereas Viral Hepatitis testing is usually not included, as most syndromic approaches are limited to laboratory assays and not conducted at the Point-of-Care.
Consequently, HIV cases are well-diagnosed, but awareness of viral Hepatitis status remains low, with less than 20% of those infected being aware of their status.
This highlights the need for a combined screening approach at the Point-of-Care to better manage the epidemics and link key populations to care.
In response to this demand, we have developped the MagIA IBC test. This specialized test is designed for the detection of active infections and specifically screens for anti-HIV, anti-HCV, and HBsAg in capillary blood samples.
Therfore, MagIA IBC test enables the simultaneous detection of HIV, Hepatitis B & C infections. Swift and accurate identification of the presence or absence of these pathogens supports timely decision-making regarding treatment and infection control.
